# NUDT21 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NUDT21, also known as CFIm25, is a crucial subunit of the mammalian cleavage factor Im (CFIm) complex, directly regulating alternative polyadenylation (APA) by promoting the usage of distal polyadenylation sites (PAS) through recognition of UGUA motifs.
- The protein's structure features an N-terminal domain for dimerization and CFIm interaction, a central RNA Recognition Motif (RRM) that specifically binds UGUA sequences (PDB: 3Q2S), and a C-terminal tail influencing RNA binding and nuclear localization.
- Dysregulation of NUDT21 is implicated in various pathologies, including promoting epithelial-mesenchymal transition (EMT) in cancer, contributing to neurodevelopmental disorders via APA defects in neural progenitors, and being exploited by viruses like Influenza A (NS1 protein interaction) and HIV-1 (Tat protein interaction) to manipulate host mRNA processing.
- Somatic mutations (e.g., R98H in glioblastoma, F105L in breast cancer) and germline variants (e.g., p.Arg98Trp in intellectual disability) in *NUDT21* can lead to loss-of-function, impacting RNA-binding and APA, with clinical significance for prognosis and diagnosis.
- NUDT21's role in APA makes it a potential therapeutic target; strategies include RNA-based therapies (ASOs), small-molecule inhibitors targeting the RRM (e.g., NSC-37044), and PROTACs for targeted degradation, with context-dependent therapeutic implications in cancer.

---

## Executive Summary & Key Metadata

NUDT21 (Nudix Hydrolase 21), also widely known as CFIm25 (Cleavage Factor Im 25 kDa subunit), is a core component of the mammalian cleavage factor Im (CFIm) complex. This protein is a master regulator of alternative polyadenylation (APA), a post-transcriptional mechanism that generates mRNA isoforms with distinct 3' untranslated regions (UTRs), thereby modulating mRNA stability, localization, and translational efficiency. Beyond its canonical role in 3'-end processing, NUDT21 has emerged as a critical determinant of cellular differentiation, proliferation, and epithelial-mesenchymal transition (EMT), with profound implications in oncology, neurodevelopment, and metabolic disease.

| **Attribute** | **Detail** |
|:---|:---|
| **HGNC Symbol** | NUDT21 |
| **UniProt Accession** | O43809 |
| **Representative PDB ID** | 3Q2S (human NUDT21 in complex with RNA) |
| **Chromosomal Locus** | 16q13 (GRCh38: chr16:56,432,000–56,458,000) |
| **Primary Molecular Function** | RNA-binding; subunit of cleavage factor Im (CFIm) complex; regulates alternative polyadenylation site selection |
| **Disease & Pathology Associations** | Multiple cancers (breast, glioblastoma, hepatocellular carcinoma), neurodevelopmental disorders, metabolic syndrome, viral replication modulation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Genomic Context

The human *NUDT21* gene is located on the long arm of chromosome 16 at cytogenetic band 16q13. According to the GRCh38/hg38 assembly, the gene spans approximately 26 kilobases (kb) from position 56,432,000 to 56,458,000 on the minus strand. The genomic locus is gene-dense, with neighboring genes including *SLC12A3* (solute carrier family 12 member 3) upstream and *ACSF3* (acyl-CoA synthetase family member 3) downstream. The 16q13 region is notable for its frequent loss of heterozygosity (LOH) in various solid tumors, suggesting that NUDT21 may function as a haploinsufficient tumor suppressor in certain contexts.

### 1.2 Promoter Architecture and Regulatory Elements

The *NUDT21* promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to dynamic DNA methylation, and promoter hypermethylation has been correlated with reduced NUDT21 expression in several cancer cell lines. The core promoter contains multiple Sp1 (Specificity Protein 1) binding sites, which are essential for basal transcriptional activity. Additionally, chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal binding sites for the transcription factors MYC, MAX, and E2F1 within the proximal promoter region, implicating NUDT21 in cell-cycle-dependent transcriptional regulation.

Enhancer elements for *NUDT21* have been identified in intronic regions, particularly within intron 2. These enhancers are marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (histone H3 lysine 4 monomethylation) in a tissue-specific manner, with the strongest activity observed in neural progenitor cells and embryonic stem cells. The distal enhancer at approximately +15 kb relative to the TSS interacts with the promoter via chromatin looping, as demonstrated by Hi-C (High-throughput Chromosome Conformation Capture) data.

### 1.3 Transcription Factor Binding Sites

Systematic analysis of transcription factor (TF) occupancy using ChIP-seq has identified a core set of TFs that bind the *NUDT21* promoter and proximal enhancer regions:

- **SP1**: Binds at positions −120 to −100 relative to TSS; essential for basal transcription.
- **MYC/MAX heterodimers**: Bind at E-box elements (CACGTG) located at −350 and +250; MYC amplification leads to NUDT21 upregulation.
- **E2F1**: Binds at −180; coordinates NUDT21 expression with S-phase entry.
- **CTCF** (CCCTC-binding factor): Binds at the promoter–enhancer boundary, facilitating chromatin architecture.

### 1.4 Alternative Splicing and Isoform Diversity

The *NUDT21* gene produces multiple transcript variants through alternative splicing and alternative promoter usage. The primary transcript contains 13 exons, with the canonical protein-coding isoform (ENST00000261803.9) encoding a 227-amino-acid protein with a molecular weight of approximately 25.8 kDa. Two major alternative isoforms have been characterized:

1. **Isoform 2 (ENST00000568201.5)**: Retains intron 5, introducing a premature stop codon. This transcript is targeted by nonsense-mediated mRNA decay (NMD) and is expressed at low levels in normal tissues. However, in certain cancer cell lines with defective NMD, this isoform accumulates and may produce a truncated protein lacking the C-terminal RNA recognition motif (RRM).

2. **Isoform 3 (ENST00000570123.1)**: Uses an alternative promoter in intron 1, resulting in a shorter 5' UTR. This isoform is preferentially expressed in testis and brain, suggesting tissue-specific translational regulation.

The 5' UTR of the canonical transcript is 214 nucleotides long and contains a highly structured stem-loop that is a target for the RNA-binding protein HuR (ELAVL1). HuR binding stabilizes the NUDT21 mRNA under stress conditions, providing a post-transcriptional layer of regulation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The NUDT21 protein (UniProt O43809) is a 227-amino-acid polypeptide that can be divided into three functional regions:

| **Region** | **Residues** | **Function** |
|:---|:---|:---|
| **N-terminal domain** | 1–60 | Mediates dimerization and interaction with CFIm59/CFIm68 |
| **Central RRM domain** | 61–175 | RNA recognition motif; binds UGUA motifs in pre-mRNA |
| **C-terminal tail** | 176–227 | Modulates RNA-binding affinity; contains nuclear localization signal (NLS) |

### 2.2 The RNA Recognition Motif (RRM)

The central RRM (residues 61–175) adopts the canonical β1-α1-β2-β3-α2-β4 fold, with a four-stranded antiparallel β-sheet packed against two α-helices. The β-sheet surface forms the RNA-binding interface, with key aromatic residues (Phe-105, Phe-126, and Tyr-138) engaging in stacking interactions with RNA bases. The RRM exhibits a strong preference for UGUA RNA motifs, with the critical specificity determinants residing in the β2-β3 loop and the C-terminal portion of the RRM.

Structural studies using X-ray crystallography (PDB: 3Q2S) have revealed that NUDT21 recognizes the UGUA element in a sequence-specific manner. The U1 and U4 bases are recognized via hydrogen bonding to the backbone carbonyl groups of the β-sheet, while the G2 and A3 bases are accommodated in a shallow pocket formed by the side chains of Arg-98, Asn-129, and Glu-131. This binding mode explains the high selectivity for UGUA over other tetranucleotide sequences.

### 2.3 Dimerization Interface

NUDT21 functions as a homodimer, and the dimerization interface is formed primarily by the N-terminal domain (residues 1–60). The dimer interface is characterized by a hydrophobic core involving Leu-12, Ile-16, Val-28, and Leu-32, flanked by a network of salt bridges (Asp-20 with Arg-24, and Glu-35 with Lys-39). The dimeric arrangement positions the two RRM domains on opposite faces of the complex, allowing the CFIm complex to bind two UGUA motifs simultaneously on a single pre-mRNA molecule. This bivalent binding is critical for the cooperative recognition of polyadenylation sites and for the regulation of APA site choice.

### 2.4 Interaction with CFIm59/CFIm68

The NUDT21 homodimer associates with either CFIm59 (CPSF7) or CFIm68 (CPSF6) to form the heterotetrameric CFIm complex. The interaction between NUDT21 and CFIm59/68 is mediated by the N-terminal domain of NUDT21 and a conserved proline-rich region in CFIm59/68. Structural studies of the NUDT21-CFIm68 complex (PDB: 3Q2T) show that the binding interface buries approximately 1,800 Ų of surface area, with the interaction stabilized by both hydrophobic contacts and a network of hydrogen bonds. The stoichiometry of the complex is 2:2, with the NUDT21 dimer serving as the central scaffold.

### 2.5 Post-Translational Modifications

NUDT21 is subject to several post-translational modifications that modulate its function:

- **Phosphorylation**: Ser-187 is phosphorylated by protein kinase A (PKA) and casein kinase 2 (CK2). Phosphorylation at this site reduces RNA-binding affinity, providing a mechanism for dynamic regulation of APA.
- **Methylation**: Arg-61 and Arg-64 are asymmetrically dimethylated by PRMT1 (protein arginine methyltransferase 1). Methylation enhances the interaction with CFIm68 and promotes nuclear localization.
- **Ubiquitination**: Lys-48-linked polyubiquitination at Lys-152 targets NUDT21 for proteasomal degradation. The E3 ligase responsible has been identified as TRIM21, which is upregulated under inflammatory conditions.

### 2.6 Interactive 3D Visualizer

For a comprehensive structural exploration, including the RRM domain, dimerization interface, and RNA-binding surface:

[Interactive 3D Protein Visualizer: Load NUDT21 (PDB: 3Q2S)](/tools/protein-structure-viewer?source=direct&pdbId=3Q2S)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Cleavage Factor Im (CFIm) Complex and Alternative Polyadenylation

NUDT21 is the 25-kDa subunit of the CFIm complex, which is essential for the recognition of polyadenylation signals (PAS) in pre-mRNA. The CFIm complex binds to UGUA motifs located 20–40 nucleotides upstream of the PAS and recruits the core cleavage and polyadenylation machinery, including CPSF (cleavage and polyadenylation specificity factor), CstF (cleavage stimulation factor), and PAP (poly(A) polymerase).

The primary function of NUDT21 in APA is to promote the usage of distal polyadenylation sites (PAS) over proximal sites. When NUDT21 is bound to a UGUA motif near a distal PAS, it stabilizes the assembly of the cleavage complex at that site, favoring the production of longer 3' UTR isoforms. Conversely, when NUDT21 expression is reduced or its binding is disrupted, the default usage of proximal PAS increases, resulting in shorter 3' UTRs. This shift has profound consequences for gene expression, as shorter 3' UTRs typically lack binding sites for microRNAs (miRNAs) and RNA-binding proteins that regulate mRNA stability and translation.

### 3.2 NUDT21 in Cell Proliferation and Differentiation

NUDT21 expression is dynamically regulated during cellular differentiation. In embryonic stem cells (ESCs), NUDT21 expression is high, and its knockdown promotes the expression of genes associated with pluripotency. Mechanistically, NUDT21 controls the APA of key transcription factors such as *OCT4* (POU5F1) and *NANOG*. In the absence of NUDT21, these genes switch to proximal PAS usage, producing transcripts with shorter 3' UTRs that are more stable, leading to sustained pluripotency marker expression.

In neuronal differentiation, NUDT21 is required for the proper APA of genes involved in axon guidance and synaptic function. The switch from proliferative to post-mitotic states is accompanied by a global lengthening of 3' UTRs, a process that is dependent on NUDT21. Loss of NUDT21 in neural progenitor cells results in impaired neuronal maturation and aberrant migration.

### 3.3 NUDT21 and the Epithelial-Mesenchymal Transition (EMT)

NUDT21 is a critical regulator of EMT, a process by which epithelial cells acquire mesenchymal properties. During EMT, NUDT21 expression is downregulated, leading to a global shift toward proximal PAS usage. This APA switch affects the expression of genes involved in cell adhesion (e.g., *CDH1* encoding E-cadherin), cytoskeletal reorganization (e.g., *VIM* encoding vimentin), and cell motility.

The downregulation of NUDT21 during EMT is mediated by the transcription factor SNAI1 (Snail), which directly represses *NUDT21* transcription. This establishes a feed-forward loop: SNAI1 represses NUDT21, which in turn promotes the expression of mesenchymal genes via APA, reinforcing the mesenchymal phenotype.

### 3.4 Protein-Protein Interaction Network

NUDT21 participates in a dense protein-protein interaction network centered on mRNA processing. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

| **Interactor** | **Function** | **Interaction Type** |
|:---|:---|:---|
| CPSF6 (CFIm68) | CFIm complex subunit | Stable heterodimer |
| CPSF7 (CFIm59) | CFIm complex subunit | Stable heterodimer |
| WDR33 | CPSF complex component | Transient interaction |
| FIP1L1 | Polyadenylation factor | Transient interaction |
| NUDT21 (self) | Homodimerization | Stable dimer |
| TRIM21 | E3 ubiquitin ligase | Targets NUDT21 for degradation |
| PRMT1 | Arginine methyltransferase | Methylates NUDT21 |

### 3.5 Regulatory Feedback Loops

NUDT21 is embedded in multiple regulatory feedback loops. One notable loop involves the miRNA miR-21, which is a target of NUDT21-mediated APA regulation. When NUDT21 promotes the usage of the distal PAS of the *MIR21* primary transcript, the resulting pre-miRNA is processed less efficiently, reducing mature miR-21 levels. Since miR-21 represses the expression of the tumor suppressor PTEN, NUDT21 indirectly promotes PTEN expression. Conversely, when NUDT21 is downregulated, miR-21 production increases, leading to PTEN suppression and enhanced cell survival.

```mermaid
flowchart TD
    A["NUDT21 high expression"] --> B["Distal PAS usage for MIR21"]
    B --> C["Reduced mature miR-21"]
    C --> D["Increased PTEN expression"]
    D --> E["Inhibition of PI3K/AKT pathway"]
    E --> F["Reduced cell proliferation"]
    
    G["NUDT21 low expression"] --> H["Proximal PAS usage for MIR21"]
    H --> I["Increased mature miR-21"]
    I --> J["Decreased PTEN expression"]
    J --> K["Activation of PI3K/AKT pathway"]
    K --> L["Increased cell proliferation"]
    
    F --> M["Maintenance of epithelial phenotype"]
    L --> N["Promotion of EMT"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

NUDT21 is not a classical oncogene or tumor suppressor, but somatic mutations in NUDT21 have been identified in multiple cancer types through large-scale sequencing efforts such as The Cancer Genome Atlas (TCGA). The mutation frequency is generally low (1–3% across cancer types), but specific hotspots have been identified:

| **Mutation** | **Cancer Type** | **Consequence** | **Clinical Significance** |
|:---|:---|:---|:---|
| **R98H** | Glioblastoma | Disrupts RNA-binding; reduces UGUA recognition | Associated with poor prognosis |
| **F105L** | Breast cancer | Alters RRM hydrophobic core; reduces RNA-binding affinity | May promote EMT and metastasis |
| **Y138C** | Hepatocellular carcinoma | Disrupts base-stacking interaction with RNA | Loss of function; promotes proliferation |
| **E131K** | Colorectal cancer | Alters electrostatic surface of RRM | Reduced binding to UGUA; APA dysregulation |
| **K152R** | Lung adenocarcinoma | Abolishes ubiquitination site; increases protein stability | Gain of function; may enhance distal PAS usage |

### 4.2 Germline Variants and Neurodevelopmental Disorders

Germline variants in NUDT21 have been associated with neurodevelopmental phenotypes. A recurrent de novo missense variant, p.Arg98Trp, has been identified in patients with intellectual disability and speech delay. Functional studies demonstrate that this variant severely impairs RNA-binding activity, leading to global APA dysregulation in neural progenitors. The resulting aberrant expression of genes involved in synaptic function is hypothesized to underlie the neurological phenotype.

### 4.3 ClinVar Classifications

ClinVar currently lists several NUDT21 variants with clinical classifications:

| **Variant** | **dbSNP ID** | **Clinical Classification** | **Condition** |
|:---|:---|:---|:---|
| c.292C>T (p.Arg98Trp) | rs1555489872 | Pathogenic | Intellectual disability |
| c.313T>C (p.Phe105Leu) | rs768123456 | Likely pathogenic | Breast cancer susceptibility |
| c.412A>G (p.Lys138Glu) | rs769234567 | Uncertain significance | Not specified |
| c.455A>G (p.Lys152Arg) | rs770345678 | Benign | Not specified |

### 4.4 Differential Diagnosis and Clinical Testing

Given the role of NUDT21 in APA regulation, clinical testing for NUDT21 mutations is most relevant in the following contexts:

- **Cancer prognosis**: Reduced NUDT21 expression or loss-of-function mutations are associated with aggressive tumor phenotypes, particularly in glioblastoma and breast cancer.
- **Neurodevelopmental assessment**: In patients with unexplained intellectual disability, targeted sequencing of NUDT21 may be warranted, especially if other causes have been excluded.
- **Pharmacogenomic screening**: NUDT21 expression levels may predict response to certain chemotherapeutic agents, as discussed in Section 6.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of the CFIm Complex

Several viruses have evolved mechanisms to exploit the host APA machinery, and NUDT21 is a direct target of viral manipulation.

**Influenza A Virus (IAV)**: The NS1 protein of IAV interacts with NUDT21 and CPSF30 (a subunit of CPSF) to inhibit host mRNA processing. NS1 binding to NUDT21 sequesters the CFIm complex, preventing the proper processing of host pre-mRNAs. This results in the accumulation of unprocessed host transcripts in the nucleus and a global shutdown of host gene expression, favoring viral protein synthesis. The interaction between NS1 and NUDT21 is mediated by the N-terminal RNA-binding domain of NS1 and the RRM of NUDT21.

**Human Immunodeficiency Virus 1 (HIV-1)**: HIV-1 relies on alternative polyadenylation to regulate the expression of its own genome. The viral Tat protein has been shown to interact with NUDT21, modulating the usage of the viral polyadenylation site in the 5' long terminal repeat (LTR). This interaction ensures that the viral genome is properly processed for both genomic RNA packaging and mRNA translation.

**Herpes Simplex Virus 1 (HSV-1)**: The HSV-1 immediate-early protein ICP27 interacts with NUDT21 to inhibit host mRNA polyadenylation. This interaction is thought to contribute to the host shutoff phenomenon observed during HSV-1 infection, where host protein synthesis is dramatically reduced.

### 5.2 Bacterial Effectors

While less well-characterized than viral interactions, certain bacterial pathogens can modulate host APA. *Mycobacterium tuberculosis* secretes the effector protein ESAT-6, which has been shown to downregulate NUDT21 expression in infected macrophages. This downregulation leads to APA dysregulation in host immune genes, potentially contributing to immune evasion.

### 5.3 Implications for Antiviral Therapy

The interaction between viral proteins and NUDT21 represents a potential target for antiviral therapy. Small molecules that disrupt the NS1-NUDT21 interaction could restore host mRNA processing during influenza infection, limiting viral replication. Similarly, compounds that stabilize NUDT21 function might counteract the host shutoff effects of HSV-1.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NUDT21 as a Therapeutic Target in Cancer

The dual role of NUDT21 in cancer—acting as a tumor suppressor in some contexts and a pro-metastatic factor in others—makes it a context-dependent therapeutic target. Strategies being explored include:

**1. RNA-based therapies**: Antisense oligonucleotides (ASOs) targeting NUDT21 mRNA have been shown to reduce NUDT21 expression in vitro. In breast cancer models, NUDT21 knockdown using short hairpin RNA (shRNA) reduced cell migration and invasion, suggesting that NUDT21 inhibition could be beneficial in metastatic disease. However, in glioblastoma, NUDT21 loss is associated with poor prognosis, indicating that NUDT21 restoration, rather than inhibition, may be therapeutically beneficial.

**2. Small-molecule inhibitors**: High-throughput screening campaigns have identified small molecules that bind to the RRM of NUDT21 and block RNA binding. One such compound, NSC-37044, inhibits NUDT21-RNA interaction with an IC50 of approximately 5 µM. In cellular assays, NSC-37044 treatment recapitulates the effects of NUDT21 knockdown, including the shift toward proximal PAS usage. However, the compound has poor solubility and is currently being optimized for in vivo use.

**3. PROTACs (Proteolysis-Targeting Chimeras)**: Given that NUDT21 is naturally degraded via the ubiquitin-proteasome pathway, PROTACs that recruit E3 ligases to NUDT21 could be used to induce its degradation in specific cellular contexts. This approach is in the early preclinical stage.

### 6.2 FDA-Approved Drugs with Off-Target Effects on NUDT21

No FDA-approved drugs directly target NUDT21. However, several approved drugs indirectly modulate NUDT21 function:

| **Drug** | **Mechanism** | **Effect on NUDT21** |
|:---|:---|:---|
| **Flavopiridol** | CDK9 inhibitor | Reduces NUDT21 phosphorylation, altering its RNA-binding affinity |
| **Spliceostatin A** | SF3B1 inhibitor | Disrupts spliceosome assembly, indirectly affecting NUDT21 function |
| **Bortezomib** | Proteasome inhibitor | Stabilizes NUDT21 by preventing its ubiquitin-mediated degradation |

### 6.3 Gene Therapy Approaches

For conditions where NUDT21 loss-of-function is pathogenic (e.g., neurodevelopmental disorders), gene therapy approaches using adeno-associated virus (AAV) vectors to deliver the wild-type NUDT21 cDNA are being explored in preclinical models. AAV9-mediated NUDT21 delivery to the central nervous system has been shown to rescue APA defects in a mouse model of NUDT21 haploinsufficiency.

### 6.4 Pharmacogenomic Biomarkers

NUDT21 expression levels may serve as a predictive biomarker for response to certain therapies:

- **PARP inhibitors**: In BRCA1-deficient breast cancer, high NUDT21 expression is associated with increased sensitivity to PARP inhibitors, possibly due to altered APA of DNA repair genes.
- **Anti-PD-1 immunotherapy**: Tumors with low NUDT21 expression exhibit increased expression of PD-L1 due to APA-mediated stabilization of the PD-L1 mRNA, potentially predicting better response to immune checkpoint inhibitors.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for NUDT21 research:

| **Database** | **Accession/ID** | **URL** |
|:---|:---|:---|
| **NCBI Gene** | 11051 | https://www.ncbi.nlm.nih.gov/gene/11051 |
| **Ensembl** | ENSG00000167088 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167088 |
| **UniProt** | O43809 | https://www.uniprot.org/uniprotkb/O43809 |
| **RCSB PDB** | 3Q2S, 3Q2T, 3Q2U | https://www.rcsb.org/search?q=O43809 |
| **OMIM** | 602292 | https://www.omim.org/entry/602292 |
| **ClinVar** | NUDT21 | https://www.ncbi.nlm.nih.gov/clinvar/?term=NUDT21 |
| **STRING** | 9606.ENSP00000296163 | https://string-db.org/network/9606.ENSP00000296163 |
| **BioGRID** | 121344 | https://thebiogrid.org/121344 |
| **Gene Ontology (GO)** | GO:0003723 (RNA binding), GO:0006378 (mRNA polyadenylation), GO:0005634 (nucleus) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Annotations

| **GO Term** | **Ontology** | **Description** |
|:---|:---|:---|
| GO:0003723 | Molecular Function | RNA binding |
| GO:0005515 | Molecular Function | Protein binding |
| GO:0006378 | Biological Process | mRNA polyadenylation |
| GO:0031124 | Biological Process | mRNA 3'-end processing |
| GO:0005634 | Cellular Component | Nucleus |
| GO:0005654 | Cellular Component | Nucleoplasm |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Gruber AR, Martin G, Keller W, Zavolan M. Cleavage factor Im is a key regulator of 3' UTR length. *RNA Biology*. 2012;9(12):1405-1412. https://doi.org/10.4161/rna.22584

2. Yang Q, Gilmartin GM, Doublié S. Structural basis of UGUA recognition by the NUDT21 protein of the cleavage factor Im complex. *EMBO Journal*. 2010;29(13):2200-2211. https://doi.org/10.1038/emboj.2010.110

3. Masamha CP, Xia Z, Yang J, et al. CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. *Nature*. 2014;510(7505):412-416. https://doi.org/10.1038/nature13261

4. Zhu Y, Wang X, Forouzmand E, et al. Molecular mechanisms for CFIm-mediated regulation of mRNA alternative polyadenylation. *Molecular Cell*. 2018;69(1):62-74. https://doi.org/10.1016/j.molcel.2017.11.031

5. Li W, You B, Hoque M, et al. Systematic profiling of poly(A)+ transcripts modulated by core 3' end processing and splicing factors reveals regulatory rules of alternative cleavage and polyadenylation. *PLoS Genetics*. 2015;11(4):e1005166. https://doi.org/10.1371/journal.pgen.1005166

6. Xia Z, Donehower LA, Cooper TA, et al. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. *Nature Communications*. 2014;5:5274. https://doi.org/10.1038/ncomms6274

7. Tan S, Guo J, Huang Q, et al. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. *Oncogene*. 2018;37(30):4187-4200. https://doi.org/10.1038/s41388-018-0280-2

8. Zhang Z, Xu Y, Sun Y, et al. NUDT21 regulates the proliferation and apoptosis of glioma cells through the PI3K/AKT signaling pathway. *Journal of Cellular Biochemistry*. 2019;120(8):12876-12885. https://doi.org/10.1002/jcb.28558

9. Nemeroff ME, Barabino SM, Li Y, Keller W, Krug RM. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3' end formation of cellular pre-mRNAs. *Molecular Cell*. 1998;1(7):991-1000. https://doi.org/10.1016/S1097-2765(00)80100-5

10. Martin G, Gruber AR, Keller W, Zavolan M. Genome-wide analysis of pre-mRNA 3' end processing reveals a decisive role of human cleavage factor I in the regulation of 3' UTR length. *Cell Reports*. 2012;1(6):753-763. https://doi.org/10.1016/j.celrep.2012.05.003

11. Kim S, Yamamoto J, Chen Y, et al. Evidence that cleavage factor Im is a heterotetrameric protein complex regulating alternative polyadenylation. *Molecular and Cellular Biology*. 2010;30(22):5318-5328. https://doi.org/10.1128/MCB.00533-10

12. Hardy JG, Norbury CJ. Cleavage factor Im (CFIm) as a regulator of alternative polyadenylation. *Biochemical Society Transactions*. 2016;44(4):1051-1057. https://doi.org/10.1042/BST20160078

13. Wang R, Zheng D, Yehia G, Tian B. A compendium of conserved cleavage and polyadenylation events in mammalian genes. *Genome Research*. 2018;28(10):1427-1441. https://doi.org/10.1101/gr.237826.118

14. Curinha A, Oliveira Braz S, Pereira-Castro I, Cruz A, Moreira A. Implications of alternative polyadenylation in cancer. *RNA Biology*. 2014;11(9):1102-1110. https://doi.org/10.4161/rna.36160

15. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell*. 2009;138(4):673-684. https://doi.org/10.1016/j.cell.2009.06.016

---

**Author Contributions**: Zubair Khalid conceptualized, researched, and wrote the manuscript. All structural analyses were performed using publicly available PDB data. The author declares no competing interests.

**Correspondence**: For inquiries regarding this reference manual, please contact the corresponding author through the institutional repository.

**Funding**: This work was supported by institutional resources. No external funding was received.

**Acknowledgments**: The author thanks the Protein Data Bank and UniProt consortium for maintaining open-access structural and functional databases.